Related Experiment Videos
Is there a future for cell kinetic measurements using IdUrd or BdUrd?
1Department of Radiation Oncology, UH Leuven, Leuven, Belgium.
International Journal of Radiation Oncology, Biology, Physics
|February 15, 2001
Summary
Predicting tumor proliferation during radiotherapy is crucial for head and neck cancer patients. Potential doubling time (Tpot) measurements are not reliable predictors, but labeling index (LI) shows promise for personalized accelerated treatment schedules.
Area of Science:
- Oncology
- Radiation Oncology
- Cancer Biology
Background:
- Increasing treatment time in radiotherapy for head and neck cancer correlates with reduced local control, likely due to tumor cell proliferation.
- Accelerated radiotherapy schedules aim to improve local control but may cause severe acute reactions and are not beneficial for all tumor types.
- Predicting which tumors will proliferate rapidly is essential for tailoring accelerated radiotherapy, potentially improving outcomes and minimizing toxicity.
Purpose of the Study:
- To investigate if the potential doubling time (Tpot) measured before treatment correlates with the effective doubling time (Tp) during radiotherapy.
- To determine if Tpot can serve as a reliable predictor for identifying tumors that would benefit from accelerated radiotherapy schedules.
Main Methods:
- Tpot calculation based on labeling index (LI) and DNA synthesis time (Ts) measured via flow cytometry.
- Analysis of pretreatment kinetic parameters, including LI and Tpot, in relation to local control in head and neck cancer patients.
Main Results:
- A multicenter analysis indicated that labeling index (LI), not Tpot, is the only pretreatment kinetic parameter with evidence of association with local control.
- Pretreatment Tpot measurements using flow cytometry proved to be an inaccurate and insufficiently reproducible predictor for radiotherapy outcomes in head and neck cancer.
- Assay variability, intratumor heterogeneity, and cell admixtures limit the clinical utility of Tpot measurements.
Conclusions:
- Pretreatment Tpot measurements are a weak predictor of radiotherapy outcomes in head and neck cancer.
- Labeling index (LI) measured by immunohistochemistry shows potential as a more accurate and reproducible method for clinical cell kinetic measurements.
- Immunohistochemistry for LI may offer independent information, representing a future direction for personalized radiotherapy strategies.